LEUKINE
LOE Approachingsargramostim
BLAINTRAVENOUSVIALPriority Review
Approved
Mar 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
LEUKINE (sargramostim) is (gm-csf) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal expansion, and differentiation of hematopoietic progenitor cells. First approved in 1991.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEUKINE (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that supports survival, proliferation, and differentiation of hematopoietic progenitor cells. It induces partially committed progenitor cells to divide and differentiate into neutrophils, monocytes, macrophages, and dendritic cells, while also activating mature granulocytes and macrophages. The drug is used in patients requiring hematopoietic support, particularly in bone marrow transplant settings and chemotherapy-induced neutropenia.
$0.003BPart D
LOE ApproachingAs an aging biologic approaching loss of exclusivity with modest Part D spending ($3M in 2023), the brand team is likely in maintenance or transition mode with limited headcount expansion.
Mechanism of Action
(GM-CSF) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal expansion, and differentiation of hematopoietic progenitor cells. GM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.